Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.48 |
| ▸ | TAF1 | P21675 | 3/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198871 | 0.98 | ATR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4204399 | 0.96 | ATR (0.52) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4208726 | 0.94 | ATR (0.50) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4203815 | 0.91 | ATR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4203153 | 0.91 | ATR (0.47) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4194587 | 0.91 | ATR (0.49) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4207731 | 0.88 | ATR (0.54) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4207254 | 0.87 | ATR (0.53) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4201748 | 0.87 | ATR (0.51) | ATRPIK3CAMTORKCNH2ATRIP | |
| SCHEMBL4199383 | 0.87 | ATR (0.47) | ATRPIK3CAMTORKCNH2ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | ATR 1185/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.